W
WuXi Biologics
Sustainability Report and Carbon Intensity Rankings
Is WuXi Biologics doing their part?
Their DitchCarbon score is 51
WuXi Biologics has a DitchCarbon Score of 51 out of 100, indicating a moderate level of sustainability in their operations. This score reflects the company’s carbon intensity, which is a measure of the greenhouse gases emitted relative to the value of their output. A score of 51 suggests that WuXi Biologics is making progress but still has room for improvement in reducing their carbon intensity and enhancing their environmental performance.
This was calculated based on 30+ company specific emissions data points, the higher the score, the better. Check out our methodology.
Industry emissions intensity
Very low
Low
Medium
High
Very high
WuXi Biologics is part of the industrial manufacturing sector, which has a carbon intensity ranking of very low. Some industries are more damaging than others, this ranking gives you an indication of how carbon intensive the industry is which this company operates in.
Location emissions intensity
Very low
Low
Unknown
High
Very high
WuXi Biologics, located in China, operates in a region with a certain carbon intensity rating. The sustainability of the company’s operations is influenced by China’s overall carbon intensity, affecting its environmental impact.
Unlock 30+ emissions data points on WuXi Biologics
Get the emissions intelligence you need, no surveys required.
– Historical Scope 1, 2 and 3 emissions
– Coverage of all industries, product level data
– Emissions forecasting, assurances
Unlock 30+ emissions data points on WuXi Biologics
Get the emissions intelligence you need, no surveys required.
– Historical Scope 1, 2 and 3 emissions
– Coverage of all industries, product level data
– Emissions forecasting, assurances
9.71%
...this company is doing 9.71% better in emissions than the industry average.
WuXi Biologics, founded in 2010 and headquartered in Wuxi City, operates within the industrial manufacturing sector, specifically focusing on biologics drug development. As a leading Contract Development and Manufacturing Organization (CDMO), the company offers a comprehensive suite of services from drug discovery to commercial manufacturing, utilizing an open-access technology platform. With a seasoned leadership team and extensive capabilities, including one of the world’s largest disposable bioreactor-based manufacturing facilities, WuXi Biologics empowers clients globally with efficient and quality-driven biologics development.
emission intelligence's platform recommendations for WuXi Biologics
WuXi Biologics should undertake a thorough inventory of all Scope 1 emissions sources to identify and mitigate direct greenhouse gas emissions.
Good news, WuXi Biologics has embraced SBTi climate commitments
WuXi Biologics has pledged to align its operations and strategies with the Science Based Targets initiative to significantly reduce greenhouse gas emissions. This commitment involves setting science-based emissions reduction targets that are consistent with keeping global warming below 2 degrees Celsius.
Participating
Claim this profile
Are you associate with this company?
Help us improve our data and claim this profile.
Our methodology
Read about our emission calculation methodologies, and what the DitchCarbon Score means.
Looking for a specific company?
Search our company directory or contact us for custom data requests.